ArticleEBioMedicine2017
A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients.
Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 65 citations in OpenAlex.
- Global seroprevalence and distribution of Getah virus in domestic and wild animals: A systematic review and meta-analysis.Veterinary world · 2025Article
- Dengue and Flavivirus Co-Infections: Challenges in Diagnosis, Treatment, and Disease Management.International journal of molecular sciences · 2025Review
- Flavivirus infections and diagnostic challenges for dengue, West Nile and Zika Viruses.Npj viruses · 2025Review
- Utility of an In-Vitro Micro-Neutralizing Test in Comparison to a Plaque Reduction Neutralization Test for Dengue Virus, Japanese Encephalitis Virus, and Zika Virus Serology and Drug Screening.Pathogens (Basel, Switzerland) · 2023Article
- Article
- Hyperendemic Dengue and Possible Zika Circulation in the Westernmost Region of the Indonesian Archipelago.Viruses · 2022Article
- Combination of the Focus-Forming Assay and Digital Automated Imaging Analysis for the Detection of Dengue and Zika Viral Loads in Cultures and Acute Disease.Journal of tropical medicine · 2022Article
- Article
- Reporter Virus Neutralization Test Evaluation for Dengue and Zika Virus Diagnosis in Flavivirus Endemic Area.Pathogens (Basel, Switzerland) · 2021Article
- Convenient Auto-Processing Vector Based on Bamboo Mosaic Virus for Presentation of Antigens Through Enzymatic Coupling.Frontiers in immunology · 2021Article
- Identifying optimal capsid duplication length for the stability of reporter flaviviruses.Emerging microbes & infections · 2020Article
- Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools.The journal of venomous animals and toxins including tropical diseases · 2020Review
- Reverse genetic approaches for the development of Zika vaccines and therapeutics.Current opinion in virology · 2020Review
- Review
- A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.Nature communications · 2020Article
- Using recombination-dependent lethal mutations to stabilize reporter flaviviruses for rapid serodiagnosis and drug discovery.EBioMedicine · 2020Article
- A Simple and High-Throughput ELISA-Based Neutralization Assay for the Determination of Anti-Flavivirus Neutralizing Antibodies.Vaccines · 2020Article
- A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.bioRxiv : the preprint server for biology · 2020Article
- Serological Diagnosis of Flavivirus-Associated Human Infections.Diagnostics (Basel, Switzerland) · 2020Review
- Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement.EBioMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
The potential association of microcephaly and other congenital abnormalities with Zika virus (ZIKV) infection during pregnancy underlines the critical need for a rapid and accurate diagnosis. Due to the short duration of ZIKV viremia in infected patients, a serologic assay that detects antibody responses to viral infection plays an essential role in diagnosing patient specimens. The current serologic diagnosis of ZIKV infection relies heavily on the labor-intensive Plaque Reduction Neutralization Test (PRNT) that requires more than one-week turnaround time and represents a major bottleneck for patient diagnosis. To overcome this limitation, we have developed a high-throughput assay for ZIKV and dengue virus (DENV) diagnosis that can attain the "gold standard" of the current PRNT assay. The new assay is homogeneous and utilizes luciferase viruses to quantify the neutralizing antibody titers in a 96-well format. Using 91 human specimens, we showed that the reporter diagnostic assay has a higher dynamic range and maintains the relative specificity of the traditional PRNT assay. Besides the improvement of assay throughput, the reporter virus technology has also shortened the turnaround time to less than two days. Collectively, our results suggest that, along with the viral RT-PCR assay, the reporter virus-based serologic assay could be potentially used as the first-line test for clinical diagnosis of ZIKV infection as well as for vaccine clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.